<DOC>
	<DOCNO>NCT02846961</DOCNO>
	<brief_summary>The purpose study evaluate development anti-drug antibody biosimilar CT-P13 ass change drug concentration 1 year patient moderately severe inflammatory bowel disease .</brief_summary>
	<brief_title>Anti CT-P13 Antibody Moderate Severe Inflammatory Bowel Disease</brief_title>
	<detailed_description />
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Clinical diagnosis Crohn 's disease ulcerative colitis Tuberculosis infection Allergy CTP13</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>inflammatory bowel disease</keyword>
	<keyword>biosimilar</keyword>
	<keyword>anti-drug antibody</keyword>
	<keyword>trough drug concentration</keyword>
</DOC>